# Clinical Trials Data KIT - Document 16

# Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

## Clinical Trial: https://clinicaltrials.gov/study/NCT01752049

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Definite clinical or genetic diagnosis of HHT\n2. Known ENG or ALK1 mutation (personal or familial)\n3. Age\\>=18 years\n4. At least 5 typical (round/ovoid, not spider or linear) cutaneous telangiectasia (size range 2-5mm) on hands (not including lesions on over inter-phalangeal joints) or face\n\nExclusion Criteria:\n\n1. Contraindication to systemic beta-blocker (severe asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt heart failure, hypotension, allergy/intolerance/ hypersensitivity to timolol)\n2. Current treatment with systemic beta-blocker\n3. Current participation in other therapeutic trial for HHT\n4. Current pregnancy or breastfeeding.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the given eligibility criteria for the clinical trial, a patient with a KIT gene mutation would not be eligible, as the inclusion criteria specify a known ENG or ALK1 mutation (personal or familial). If the patient does not have a mutation in ENG or ALK1, they would not meet the necessary genetic requirement for inclusion in this trial.